/
•
•
Detailed stories on technology startups, business and economic current affairs.
A company associated with the management is said to have divested a 4% stake when it likely had access to unpublished price-sensitive information.

A little over a year ago, Gland Pharma was a star stock to own.
Shares of the Hyderabad-based injectables maker, owned by Chinese conglomerate Fosun, hit a high of Rs 4,287 in August last year—up from Rs 1,500 in its November 2020 IPO—giving it a valuation of around Rs 70,000 crore. That put it on a par with Dr Reddy’s Laboratories, which had five times the revenue of Gland.
The story stands in sharp contrast today. The stock has fallen 54% since January and its valuation is around Rs 31,000 crore. Foreign institutional investors have reduced their stake by half, …